Switzerland's Lonza H1 sales rise, lifts FY core EBITDA margin forecast

Lonza AG

22/07/2026 05:43

    

    Overview
  
Switzerland CDMO's H1 2026 sales rose 16% CER to CHF 3.4 bln
CORE EBITDA margin expanded to 34.8%, up 4.4ppts from H1 2025
Company to launch CHF 500 mln share buyback after CHI business sale

    

    Outlook
  
Lonza upgrades 2026 CORE EBITDA margin outlook to 33-34% from above 32%
Company confirms 2026 CER sales growth guidance of 11-12%
Lonza expects FX headwind of -2 to -3% on 2026 sales, minimal margin impact

    

    Result Drivers
  
BROAD-BASED DEMAND - All business platforms delivered double-digit CER sales growth, with robust demand across technologies and geographies
MARGIN EXPANSION - CORE EBITDA margin increased due to strong operational execution, maturing growth projects, operating leverage and favorable product 
FAVORABLE PHASING AND LOW PRIOR-YEAR BASE - H1-weighted sales growth benefited from favorable phasing and a lower H1 2025 base

    
Company press release: ID:nEQ2WkppVa

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
H1 Sales
 
CHF 3.40 bln
 
H1 CORE EBITDA
 
CHF 1.20 bln
 
H1 Sales Growth
 
16.00%
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Lonza Group AG is CHF658.00, about 16.7% above its July 21 closing price of CHF564.00
The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 27 three months ago

    

    Reuters Recommended Reads
  
July 21 - Switzerland's Novartis beats Q2 sales estimates on strong sales across priority brands
July 20 - Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide
July 21 - Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)